Eli Lilly and Co (LSE:LEL)
$ 56.25 0 (1.24%) Market Cap: 63.81 Bil Enterprise Value: 87.52 Bil PE Ratio: 113.84 PB Ratio: 56.38 GF Score: 82/100

Eli Lilly and Co at Citi BioPharma Conference (Virtual) Transcript

Sep 09, 2021 / 01:45PM GMT
Michael Guba;Citigroup Inc.;Healthcare Sector Specialist
Research Division

Hi. My name is Michael Guba. I'm Citi's U.S. Healthcare Sector Specialist, filling in for Andrew Baum, who's our Global Head of Healthcare Research on -- covers major pharmaceuticals here for Citi. I'm lucky enough to be joined by Anat Ashkenazi, Senior Vice President and CFO of Eli Lilly, for a quick little fireside chat here.

Taking verbose tact here, I'm here to moderate, not monopolize. So please feel free to send any of your questions to [email protected]. I'll start off with a couple of openers. But obviously, the whole point of the conference is to have a solid investor participation, so I'd appreciate anything you guys have to ask.

Anat, thank you for joining us today.

Anat Ashkenazi
Eli Lilly and Company - Senior VP & CFO

Great. Great to be here.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot